Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2000-06-28
2003-03-11
Chan, Christina Y. (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S184100, C514S017400, C514S018700, C514S019300, C530S300000, C530S325000, C530S326000, C530S327000, C530S328000
Reexamination Certificate
active
06531130
ABSTRACT:
BACKGROUND OF THE INVENTION
Introduction
Multiple sclerosis (MS) is an acquired, inflammatory, demyelinating disease of the central nervous system (CNS). In MS, cells of the immune system invade and destroy myelin, the fatty material that insulates nerves in the brain and spinal cord; other CNS cells produce a hardened sclerotic lesion (plaque) around the multiple demyelinated sites. Neurologic findings suggest lesions in separate areas of the CNS that have occurred at different times.
Multiple sclerosis (MS) is the most common autoimmune disease involving the nervous system. In the United States approximately 250,000 individuals suffer from MS. The cause of the disease is unknown, but genetic factors are important. The concordance rate among monozygotic twins is 30%, a 10-fold increase over dizygotic twins or first-degree relatives. The higher incidence rate among monozygotic twins emphasizes the importance of genetic factors, but the discordance rate of 70% among identical twins illuminates the role of nongenetic factors on disease penetrance. Among genetic factors, HLA class 11 genes exert an influence, with HLA DR2 carrying a 4-fold relative risk for northern European caucasoids.
A typical presentation of MS involves an initial course, running for several years to more than a decade, manifest by episodes of relapse followed by remission. Relapses often follow an episode of a viral infection of the upper respiratory system or gastrointestinal tract. In about one half of MS cases the disease progresses to a more chronic phase. Clinical problems may include disturbances in visual acuity, sometimes culminating in blindness; double vision; motor disturbances affecting walking and use of the hands; incoordination; bowel and bladder incontinence; spasticity; and sensory disturbances including loss of touch, pain, and temperature and proprioception. The pathology of the disease lies entirely in the central nervous system and is characterized by a classic picture of inflammation surrounding venuies and extending into the myelin sheath.
Immune responses to various components of the myelin sheath have been detected in MS patients, including myelin basic protein (MBP), proteolipid (PLP), transaldolase, and 2′,3′ cyclic nucleotide 3′phosphodiesterases (CNP), as well as two members of the immunoglobulin supergene family found in the myelin sheath, myelin oligodendroglial glycoprotein (MOG) and myelin-associated glycoprotein (MAG) (Steinman et al. (1995)
Mol. Med. Today
1:79-83). In addition, some inducible heat shock proteins, including crystallin-B, can be detected in glial cells in MS lesions and can stimulate an immune response in MS patients.
A key immune response is targeted to certain regions of myelin basic protein. The major T and B cell response in the central nervous system of MS patients who are HLA DR2 (about two thirds of patients) is directed to a region between residues 84 and 103 of MBP (Steinman (1995)
Nature
375:739-740; Warren et al. (1995)
P.N.A.S
. 92:11061-11065). The B cell response to MBP in MS has also been studied extensively. IgG purified from brain lesions reacted with the same region of MBP, p85-96, that is the immunodominant T cell epitope in MS patients who are HLA DR2b (DRB1*1501) and overlaps with the T cell epitope in MS patients who are DR2a (DRB5*0101).
Relevant Literature
Copolymer-1 is a mixture of polypeptides composed of alanine, glutamic acid, lysine, and tyrosine in a molar ratio of approximately 6:2:5:1, respectively. It is synthesized by chemically polymerizing the four amino acids forming products with average molecular weights of 23,000 daltons (U.S. Pat. No. 3,849,550). Cop 1 binds promiscuously, with high affinity and in a peptide-specific manner to purified MS-associated HLA-DR2 (DRB1*1501) and rheumatoid arthritis-associated HLA-DR1(DRB1*0101) or HLA-DR4 (DRB1*0401) molecules (Fridkis-Hareli et al. (1999)
J Immunol
162(8):4697-704). Protruding N-terminal ends of Cop 1 bound to HLA-DR1, -DR2, or -DR4 molecules were then treated with aminopeptidase 1, followed by elution, HPLC, and pool sequencing. In contrast to untreated or unbound Cop 1, this material exhibited distinct motifs at some positions with increases in levels of E at the first and second cycles, of K at the second and third cycles, and of Y (presumably at P1 of the bound peptide) at the third to fifth cycles, regardless of the HLA-DR molecule employed. No preference was seen at the following cycles that were mainly A.
Cop-1 has been recently approved as a treatment for relapsing multiple sclerosis (MS). Evidence demonstrates that Cop-1 induces active suppression of CNS-inflammatory disease in animal models (Aharoni et al. (1997)
P.N.A.S
. 94(20):10821-6). In humans, Copaxone treatment was found to lead to a significant reduction in the mean annual relapse rate and stabilization of disability. The treatment was accompanied by an elevation of serum IL-10 levels, suppression of the pro-inflammatory cytokine TNF alpha mRNA, and an elevation of the anti-inflammatory cytokines TGF-beta and IL-4 mRNAs in PBLs (Miller et al. (1998)
J Neuroimmunol
92(1-2):113-21).
Treatment of murine experimental autoimmune encephalomyelitis with a myelin basic protein peptide analog is described by Reiseter et al. (1998)
J Neuroimmunol
91(1-2):156-70. A single administration of the MBP peptide analog, Ac1-11[4Y], reduced disease severity, accompanied by a dramatic and selective loss of neutrophil pleiocytosis. A longer course of peptide therapy resulted in complete recovery from clinical signs of disease, and decreased pleiocytosis by all cell types. Wraith et al. (1989)
Cell
59:247-255 describe antigen recognition in autoimmune encephalomyelitis and the potential for peptide mediated immunotherapy. Sakai et al. (1989)
Proceedings of the National Academy of Sciences USA
86:9470-9474 describe the prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins. Karin et al. (1994)
J.E.M
. 180:2227-2237 demonstrate the reversal of experimental autoimmune encephalomyelitis by a soluble variant of a myelin basic protein epitope.
It has been reported that administration of myelin basic protein can lead to immune tolerance (see, for example, Steinman et al. (1977)
Nature
265:173; Tonegawa (1997)
J Exp Med
186(4):507-15; Hafler et al. (1997)
Ann N Y Acad Sci
835:120-31; Kennedy et al. (1997)
J Immunol
159(2):1036-44). Various forms of Ag-specific tolerance have been demonstrated, included the administration of peptide coupled splenocytes, i.p. administration in incomplete adjuvant, oral and nasal administration.
SUMMARY OF THE INVENTION
Methods and compositions are provided for the treatment of demyelinating autoimmune diseases, including experimental autoimmune encephalomyelitis and multiple sclerosis, by administering to the host a peptide comprising the ordered amino acid motif {SEQ ID NO:1} [
1
E
2
Y
3
Y
4
K
]
n
, where n is from 2 to 6. The ordered motif may start at residue 1, as shown, or may start at a different position, e.g. {SEQ ID NO:2} YYKEYYKE; {SEQ ID NO:3} YKEYYKEY; etc.
The compositions of the present invention may be synthesized by conventional methods known in the art, e.g. expression in a recombinant system, solid phase peptide synthesis, etc. The peptide is formulated in a biologically acceptable carrier, and administered by a route to enhance the autoimmune suppressive effects of the treatment. Typically, the peptides are administered to patients suffering from multiple sclerosis on a regular basis. In a preferred embodiment, the composition is lyophilized and formed into an aqueous solution suitable for sub-cutaneous injection.
REFERENCES:
patent: 3817837 (1974-06-01), Rubenstein et al.
patent: 3849550 (1974-11-01), Teitelbaum et al.
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3853914 (1974-12-01), Goldstein et al.
patent: 3905654 (1975-09-01), Tribe
patent: 4043989 (1977-08-01), Schneider et al.
patent: 4069
Ruiz Pedro José
Steinman Lawrence
Bozicevic Field & Francis LLP
Chan Christina Y.
Huynh Phuong N
Sherwood Pamela J.
The Board of Trustees of the Leland Stanford University
LandOfFree
Treatment of demyelinating autoimmune disease with ordered... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of demyelinating autoimmune disease with ordered..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of demyelinating autoimmune disease with ordered... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3023502